Invasive Pneumococcal Disease in New Zealand, 2010

More documents

Recommendations

Info

SUMMARY continuedThere were no significant regional differences (P ≤0.05) in the incidence of IPD in 2010, butwithin the Northern region disease rates were significantly higher in Counties ManukauDistrict Heath Board (DHB) than in the other three DHBs in the region.Among the 34 cases who had received ≥1 dose of PCV-7, and for whom the serotype causingdisease was known, 27 (79.4%) had IPD due to a non-PCV-7 type. Of the seven cases whohad received ≥1 dose of PCV-7 and had disease due to a PCV-7 type, five had serotype 19Fdisease, one had type 6B disease and one had type 14 disease.There has been some increase in IPD caused by non-PCV-7 serotypes since the introductionof PCV-7. This increase has been predominantly due to serotype 1 disease. An increase inserotype 1 IPD was first noted in 2007 and appears to have peaked in 2009, with the rate oftype 1 disease halving between 2009 and 2010. Except for 2009, most of the serotype 1disease has been in cases 5-34 years of age. In 2009, this type also became common amonginfants
1. INTRODUCTIONPrior to 2009, the national surveillance of invasive pneumococcal disease (IPD) inNew Zealand was solely laboratory based, with diagnostic laboratories referring invasiveisolates of Streptococcus pneumoniae to the Institute of Environmental Science and ResearchLtd (ESR) for serotyping and antimicrobial susceptibility testing. This laboratory-basedsurveillance provided information on the basic epidemiology of IPD, and the serotypes andantimicrobial susceptibility of invasive isolates. Information from this laboratory-basedsurveillance was published periodically. 1-5 In addition, between 2002 and 2007, annualreports on the antimicrobial susceptibility of isolates from IPD cases have been published onESR‟s surveillance website athttp://www.surv.esr.cri.nz/antimicrobial/streptococcus_pneumoniae.php.The first of this series of annual reports on IPD in New Zealand covered IPD in 2008 and wasbased on data available from ESR‟s national laboratory-based surveillance. 6 On 1 June 2008,the 7-valent pneumococcal conjugate vaccine (PCV-7), Prevenar®, was added to the NewZealand childhood immunisation schedule and IPD became a notifiable disease on 17 October2008. The 2009 IPD annual report was the first to be based on IPD notifications,supplemented with serotype and antimicrobial susceptibility data from ESR‟s laboratorybasedsurveillance of invasive S. pneumoniae isolates. 7Data on the IPD cases notified in 2010 is presented in this report, along with trend data forrecent years.Invasive pneumococcal disease 1 September 2011in NZ, 2010
Page 1 and 2: INVASIVE PNEUMOCOCCAL DISEASEIN NEW
Page 3 and 4: DISCLAIMERThis report or document (
Page 5 and 6: CONTENTSSUMMARY ...................
Page 7: SUMMARYA 4-dose schedule of the 7-v
Page 11 and 12: Data analyses were performed with S
Page 13 and 14: 3. RESULTSIn 2010, 535 IPD cases we
Page 15 and 16: The all-age rate of IPD in 2010 (12
Page 17: 3.4 Disease incidence by ethnicityT
Page 20 and 21: 3.7 Risk factors among IPD casesThe
Page 23 and 24: 3.10 Serotype distributionTable 9.
Page 25 and 26: Rate per 100 000The rate of disease
Page 27 and 28: 3.11 Antimicrobial susceptibilityTa
Page 29 and 30: Percent of penicillin-resistant iso
Page 31 and 32: type most frequently reported to ha
Page 33 and 34: REFERENCES1 Green MJ, Cawley PFM. I
Page 35 and 36: Appendix 1. Laboratory criteria upo
Page 37 and 38: Appendix 3. Rates of invasive pneum
Page 39 and 40: Appendix 5.2010Risk factors among i
Page 41 and 42: Appendix 7. Serotypes among invasiv
Page 43 and 44: Appendix 9. Serotype 1 invasive pne
Page 45 and 46: Appendix 11. Trends in penicillin r
Page 47 and 48: Appendix 13. Penicillin and cefotax
Page 49: Appendix 15. Trends in penicillin r

Invasive Pneumococcal Disease in New Zealand, 2010

Create successful ePaper yourself

Delete template?

Save as template?